Feed / PMI

Picard Medical, Inc.

PMI

Healthcare · 4.40 +1.6% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Picard Medical, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 29 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company+1.6% todayVolume comparison unavailable
Market group0 of 29 activeNuclear and Rare Materials · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • PMI's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if PMI's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

No new filing conclusion is available. 0 of 29 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • PMI's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods2
Price observations251
Usable filing statements47
Verified relationships2
Evidence supporting the case
  • Latest annual revenue changed +12.5% year over year.
  • Operating margin changed +43.9 percentage points in the latest annual period.
Evidence challenging the case
  • Net margin changed -67.1 percentage points in the latest annual period.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

4.40
6m+307.4%12m24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2024-12-31$4.4M
2025-12-31$4.9M+12.5%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesmixed · 4 filings
As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they…
10-Q · May 15, 2026
Product pipeline and R&Dmixed · 4 filings
The increase was primarily attributable to increased activity and phase scheduling in the new product research.
10-Q · May 15, 2026
Legal and regulatory exposurepositive · 1 filings
However, the Company believes that it has, and will maintain for some time, a strong position among total artificial heart manufacturers globally and enjoys certain competitive advantages compared to other total artificial heart manufacturers because of its t…
10-K · Mar 30, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales · EV/sales . Comparisons use only industry-matched filing peers.

Scenario scaffold

Fewer than 4 annual revenue periods; too little history to scaffold scenarios.

Price action

How the market is pricing the story

4.40+1.6% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for PMI. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for PMI. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind PMI

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MDTMedtronic plcsupplierMar 30, 2026

SynCardia TAH with Freedom Driver Components The SynCardia Total Artificial Heart incorporates the SynHall Valves, derived from the predecessor MedHall valve design originally developed by Medtronic, Inc.

ABTAbbott LaboratoriescompetitorMar 30, 2026

For example, our products are likely to compete against future products offered by larger public companies such as Abbott.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

PMI is currently a Follower in the organic co-movement group Nuclear and Rare Materials. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for PMI; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.